Assignee
CYTOMX THERAPEUTICS INC
US·72 granted patents·60 pending applications·830 citations·filing 2012–2025
Top patents by PatentIndex Score
132 records- 0198US10875913B2Methods of treatment using activatable anti-EGFR antibodiesCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·21 cites·40 claims
- 0298US10533053B2Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptorCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 14, 2020·12 cites·20 claims
- 0398US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0498US10118961B2Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWVCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 6, 2018·34 cites·13 claims
- 0598US10059762B2Anti-EGFR activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·42 cites·41 claims
- 0698US9644016B2Soluble notch receptor proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·34 cites·28 claims
- 0798US9540440B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Jan 10, 2017·31 cites·25 claims
- 0898US9309510B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Apr 12, 2016·26 cites·37 claims
- 0997US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 1097US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 1197US10138272B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 27, 2018·31 cites·43 claims
- 1297US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 1397US9562073B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·32 cites·51 claims
- 1497US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1597US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 1696US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 1796US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 1896US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 1996US8993266B2Proproteins activatable interferon alphaCYTOMX THERAPEUTICS INC·Filed 2012·Granted Mar 31, 2015·28 cites·14 claims
- 2095US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 2195US11180562B2Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodiesCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 23, 2021·5 cites·22 claims
- 2295US11028126B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jun 8, 2021·8 cites·54 claims
- 2395US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 2495US10513549B2Cleavage-activatable interferon-alpha proproteinCYTOMX THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·11 claims
- 2595US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 2695US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 2795US9856314B2Activatable antibodies having non-binding steric moieties and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2013·Granted Jan 2, 2018·15 cites·29 claims
- 2895US9737623B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Aug 22, 2017·19 cites·21 claims
- 2995US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 3094US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 3194US11867695B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 9, 2024·2 cites·26 claims
- 3294US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 3394US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 3494US9517276B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2014·Granted Dec 13, 2016·24 cites·31 claims
- 3593US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 3693US10568977B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted Feb 25, 2020·8 cites·20 claims
- 3793US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3892US12139543B2Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFRCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·1 cites·25 claims
- 3992US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 4092US10513558B2Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Dec 24, 2019·23 cites·77 claims
- 4191US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 4291US11035859B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 15, 2021·3 cites·37 claims
- 4391US2025215094A1Method of using an anti-epidermal growth factor receptor (egfr) activatable antibody to detect the presence or absence of a cleaving agent and egfrCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4490US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 4590US11667687B2Masked activatable interferon constructsCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jun 6, 2023·3 cites·30 claims
- 4690US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 4790US10261083B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2014·Granted Apr 16, 2019·14 cites·20 claims
- 4890US2024228603A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4989US2025034755A1Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5087US11220544B2Anti-CD166 antibodies and uses thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jan 11, 2022·8 cites·46 claims
Showing the top 50 of 132 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →